Reportlinker Adds Global Epigenetics Industry

NEW YORK, March 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Epigenetics Industry

http://www.reportlinker.com/p0181128/Global-Epigenetics-Industry.html

This report analyzes the Global market for Epigenetics in US$ Million by the following Application Areas: Drug Discovery, Diagnostics, and Others. Annual forecasts are provided for the period 2006 through 2015. The report profiles 39 companies including many key and niche players worldwide such as Celgene Corporation, CellCentric Ltd., CellCentric Ltd., Epigentek Group, Inc., Genpathway, Inc., Merck & Co., Inc., MGI Pharma, Inc., Millipore Corporation, OncoMethylome Sciences S.A., and Orion Genomics. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

EPIGENETICS MCP-6259

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Epigenetics: An Introduction II-1

Cancer: The Key Focus Area for Epigenetics II-1

Histone Changes as Biomarkers: An Emerging Field II-2

Future of Epigenetics II-2

2. GLOBAL MARKET OVERVIEW II-3

Scope of Epigenetics II-3

Oncology II-3

Psychiatry II-3

Outlook of Epigenetic Treatments II-4

Current and Future Analysis II-4

Market Segmentation II-4

Therapeutics II-4

Diagnostics II-5

Research Tools II-5

Epigenetics Stretching to hESC Research II-5

Epigenetics: Transforming from Special Niche to Widespread

Collection of Tools II-5

Pros and Cons of First Generation Epigenetics Drugs II-6

Advances in Epigenetics Technologies, Therapeutics and

Diagnostics II-7

Outlook for Product Positioning and Innovation II-7

Epigenetic Community Initiatives II-7

Patent Law in Japan II-8

3. COMPETITION II-9

Epigenomics Pioneers the Epigenetics Diagnostics II-9

Merck Leads HDAC Inhibitors Market II-9

Huge Potential for Novel Therapies II-9

Combination Therapy II-10

Novel Technologies II-10

4. PRODUCT OVERVIEW II-11

Epigenetics - Definition II-11

Categories of Signals in Epigenetics II-11

Introduction II-11

Etymology and Meaning II-12

Epigenetics - Molecular Base II-12

Mechanisms II-13

Chromatin Remodeling and DNA Methylation II-13

RNA Transcripts and Programmed Proteins II-15

Prions II-15

Structural Inheritance Systems II-16

Functions and Outcomes II-16

Development II-16

Medicine II-17

Evolution II-17

Epigenetics in Microorganisms II-17

5. PRODUCT LAUNCHES II-18

Epigentek Group Launches New Measures for DNA Methylation Shifts II-18

QIAGEN Introduces EpiTect® HRM™ PCR Kit II-18

Enzo Biochem Rolls Out Wide-Ranging Epigenetics Tools II-18

Applied Biosystems Unveils Novel Small RNA Expression Analysis

Solution II-19

Sigma-Aldrich Launches Imprint™ Methylated DNA Quantification Kit II-19

Sigma-Aldrich Unveils ChIP Kit for Epigenetic Research II-20

Pyrosequencing Introduces New PyroMark™ Q24 II-20

Qiagen Expands Epitect Portfolio II-20

Applied Biosystems Introduces New SOLiD™ 3 System II-21

6. RECENT INDUSTRY ACTIVITY II-22

Merck Merges with Schering-Plough II-22

Celldex Therapeutics Acquires CuraGen II-22

NCCN Upgrades Vidaza to Category 1 II-22

PrognosDx Health Obtains UCLA Epigenetics Technology Rights II-22

PROGEN Posts Positive Results from Preclinical Epigenetics

Product II-23

Pharmacyclics Announces Positive Scientific Results from PCI-

24781 Clinical Trial Targeting HDAC II-23

CellCentric Signs Agreement with Takeda II-24

Orion Genomics and Novartis Ink Multi-Year Collaboration and

License Agreement II-24

SuperGen Collaborates with GlaxoSmithKline II-24

QIAGEN to Acquire SABiosciences II-24

QIAGEN Takes Over DxS II-25

CellCentric Expands Number of Researchers II-25

Roche NimbleGen Enters into Collaboration with Sigma-Aldrich II-25

Quest Diagnostics Gains biomarker license from Epigenomics II-26

Babraham Institute Launches New Epigenomics Sequencing Facility II-26

Active Motif Enters into Licensing Agreement with City of Hope II-27

NIH to Grant US$62 Million for Epigenetic Research II-27

Rush University Medical Center Obtains US$5.5 Million Grant

from NIH II-27

Celgene Takes Over Pharmion II-28

Eisai Takes Over MGI PHARMA II-28

Affymetrix Acquires Panomics II-28

QIAGEN Takes Over Biotage's Biosystems II-29

Millipore Corporation and Agilent Technologies Collaborate II-29

Invitrogen Signs License Agreement with Genisphere II-29

Invitrogen and IMBcom Proprietary Ink Licensing Agreement II-29

OncoMethylome Sciences and QIAGEN Sign Licensing Agreement II-30

Pharmacyclics Characterizes Highly Selective HDAC Inhibitor II-30

Celgene's Vidaza Gains Approval for MDS and AML in Europe II-30

Medistem Enters into Epigenetics Collaboration II-31

Orion Geomics Obtains License for IGF2 Gene from Johns Hopkins II-31

Progen Pharmaceuticals Acquires CellGate II-31

BioServe Purchases Genomics Collaborative II-31

Sigma-Aldrich and Epigentek Signs Licensing Agreement II-32

Constellation Pharmaceuticals and BioTrove Enter into R&D

Collaboration II-32

7. RECENT RESEARCH FINDINGS II-33

Salk Institute Researchers Present Full Epigenome Map II-33

Baylor College of Medicine Recognizes Epigenetic Affects on

Obesity II-33

Prenatal Starvation Could Cause Epigenetic Modifications II-33

John Hopkins Scientists Reveal Epigenetic Modifications Take

Place Over Lifetime II-33

Advances in Epigentic Regulation Focuses on Breast Cancer II-34

8. FOCUS ON SELECT PLAYERS II-35

Celgene Corporation (US) II-35

CellCentric Ltd. (UK) II-35

Epigenomics AG (Germany) II-35

Epigentek Group, Inc. (US) II-35

Genpathway, Inc. (US) II-36

Merck & Co., Inc. (US) II-36

MGI Pharma, Inc. (US) II-36

Millipore Corporation (US) II-36

OncoMethylome Sciences S.A (Belgium) II-37

Orion Genomics (US) II-37

9. GLOBAL MARKET PERSPECTIVE II-38

Table 1: World Recent Past, Current & Future Analysis for

Epigenetics by Application Area - Drug Discovery, Diagnostics

and Others Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-38

Table 2: World 10-Year Perspective for Epigenetics by

Application Area - Percentage Breakdown of Dollar Sales for

Drug Discovery, Diagnostics, and Others Markets for Years

2006, 2009, & 2015 (includes corresponding Graph/Chart) II-39

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 39 (including Divisions/Subsidiaries - 42)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 25

Canada 1

Japan 2

Europe 11

Germany 3

The United Kingdom 4

Rest of Europe 4

Asia-Pacific (Excluding Japan) 3

------------------------------------------

To order this report:

Biotechnology Industry: Global Epigenetics Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo